12:00 AM
 | 
Aug 20, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/17 cls
Array BioPharma Inc. (NASDAQ:ARRY) Leerink Howard Liang Upgrade Outperform (from market perform) 21% $5.50
Liang also raised his target to $8 from $4 on "promising" Phase II data for MEK inhibitors selumetinib and MEK126 (formerly ARRY-162). In May, Array reported Phase II data in patients with mutant K-Ras(KRAS) locally advanced or metastatic non-small cell lung cancer (NSCLC), showing that second-line treatment with selumetinib plus docetaxel improved overall survival (OS) vs. placebo plus docetaxel. Array concurrently reported Phase II data in 29 malignant cutaneous melanoma patients with BRAF V600E mutations showing that MEK162 produced one confirmed partial response (PR), six unconfirmed PRs and nine cases of stable disease (see BioCentury, May...

Read the full 754 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >